A first in the world trial looking at new treatment options for patients with melanoma that has spread to the brain is set to commence at The Alfred, potentially helping patients add years to their lives.
Clinical Trials
Choroidal melanoma treatment continues to show encouraging results at 9 months
Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.
Neoadjuvant Initiation of Pembrolizumab Improves Outcomes vs Adjuvant Therapy Alone in Advanced Melanoma
Treatment with neoadjuvant and adjuvant pembrolizumab (Keytruda) led to improved event-free survival (EFS) compared with adjuvant pembrolizumab alone for patients with resectable stage III or IV melanoma, a study published in The New England Journal of Medicine found.
Consistent Durable Responses Are Observed for Lifileucel in Melanoma Regardless of IL-2 Doses
Findings from a post hoc analysis of the phase 2 C-144-01 trial (NCT02360579) suggest that regardless of the number of IL-2 doses administered, lifileucel (LN-144) delivered durable and objective responses in patients with advanced melanoma. These data were presented during the 2022 European Society for Medical Oncology Immuno-Oncology Congress.